The Questionable Economic Case for Value-Based Drug Pricing in Market Health Systems

Value in Health

Volumn 20, Issue 2, 2017, Pages 278-282

  Pauly, Mark V ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

health care markets; insurance; pharmaceuticals; value based pricing

Indexed keywords

ARTICLE; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC MODEL; HEALTH CARE; PATENT; PHARMACOECONOMICS; PRIORITY JOURNAL; PROFIT; PUBLIC HEALTH INSURANCE; QUALITY ADJUSTED LIFE YEAR; ECONOMIC ASPECT; ECONOMICS; PURCHASING; THEORETICAL MODEL; UNITED STATES;

DRUG COSTS; DRUG INDUSTRY; ECONOMIC COMPETITION; ECONOMICS, PHARMACEUTICAL; MODELS, THEORETICAL; PATENTS AS TOPIC; UNITED STATES; VALUE-BASED PURCHASING;

EID: 85013665519     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2016.11.017     Document Type: Article

References (9)

1. [1] Claxton, K., Sculpher, M., Palmer, S., Culyer, A.J., Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?. Health Econ 24 (2015), 1–7.
2. [2] Institute for Clinical and Economic Review Comparative Effectiveness Public Advisory Council. PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks. Final Report. 2015, Institute for Clinical and Economic Review, Boston, MA.
3. [3] Loftus P. New class of cholesterol drugs should cost much less, report says. September 8, 2015. Available from: http://www.wsj.com/articles/new-class-of-cholesterol-drugs-should-cost-much-less-report-says-1441752760. [Accessed July 12, 2016].
4. [4] Pfeifer S. New prescription drugs can help patients, but their high prices elicit ire. September 21, 2015. Available from: http://www.latimes.com/business/la-fi-agenda-specialty-drugs-20150921-story.html. [Accessed July 12, 2016].
5. [5] Pollack, A., New drug sharply lowers cholesterol, but it's costly. The New York Times, July 25, 2015;Sect. B, 1.
6. [6] Rockoff, J.D., Business News: Amgen's Repatha gets approval from FDA. The Wall Street Journal, August 28, 2015;Sect. B, 3.
7. [7] Garber, A., Jones, C., Romer, P., Insurance and incentives for medical innovation. Forum Health Econ Policy, 9(2), 2006 Article 4.
8. [8] Jenkins, H.W. Jr, Libertarian dream of pharmaceuticals. The Wall Street Journal, October 31, 2015;Sect. A, 11.
9. [9] Internal Revenue Service. SOI tax stats: individual statistical tables by size of adjusted gross income. Individual complete report (publication 1304), Table 1.1, Tax Year 2013. Available from: https://www.irs.gov/uac/SOI-Tax-Stats—-Individual-Statistical-Tables-by-Size-of-Adjusted-Gross-Income. [Accessed April 27, 2016].